The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

AI automation, and more skilled staff are needed to ensure cancer patients can access potentially life-saving CAR T therapies.

The MarketWatch News Department was not involved in the creation of this content. Strategy May Bolster Blood Cancer Therapy and Move HIV Research Closer to a Cure BRONX, N.Y., March 13, 2026 ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...